N. Vogt et al., PHARMACOKINETICS AND ONCOTIC EFFECT OF HIGH-DOSE HYDROXYETHYL STARCH DURING SURGERY COMPARED TO APPLICATION OF 5-PERCENT ALBUMIN, Infusionstherapie und Transfusionsmedizin, 25(4), 1998, pp. 212-221
Objective: Medium-molecular hydroxyethyl starch (HES) is an effective
and save colloid for blood substitution up to 20 ml/kg body weight. Li
ttle is known about oncotic effects, when used above this dosage. Thes
e are important questions to be answered in order to replace expensive
albumin application in doses above 20 ml/kg. Design: Controlled, pros
pective and randomized study. Setting: Operating room of an university
hospital. Patients: 40 patients with extensive urological surgery. In
terventions: We treated blood loss in accordance with a blood substitu
tion scheme using colloids, red cells, fresh frozen plasma, and platel
ets. The HES group received 6% HES 200 0.5 and the ALB group 5% albumi
n as exclusive colloid. We determined oncotic function and characteris
tics of the plasmatic HES fraction before surgery, after application o
f 1,000 ml, 2,000 ml and 3,000 ml of colloid, and at the end of surger
y. Results: We administered a total median amount of 2,700 ml of HES (
HES group), and 2,000 ml of albumin (ALB group), which resulted in a s
ignificant difference in total serum protein of 34.4 g/l (HES) vs. 56.
5 g/l (ALB) (p < 0.01) but comparable oncotic function and colloidosmo
tic pressure (COP) of 18.0 mmHg (HES) vs. 18.8 mmHg (ALB) at the end o
f surgery. The plasmatic HES fraction was characterized by a HES conce
ntration of 6.9 g/l and an average numeric molecular weight of (median
) 51,800 Da (25-75% quantiles: 42,000-63,000 Da) and showed marked int
erindividual va;iability of the HES-related oncotic effect during all
points of measurement Conclusions: In a dosage above 20 ml/kg 6% HES 2
00 0.5 is able to maintain oncotic function and therefore to replace 5
% albumin during therapy of blood loss. However, the oncotic effect re
vealed polydisperse expression so that our results cannot be transferr
ed on high-dose administration of other HES preparations without furth
er evaluations.